EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Targeting the DSTYK-ULK1 axis rewires TNFR1 signaling to overcome treatment resistance in lung cancer

Andrea Pasquier, Cristina Viu-Idocin, Andrea Arricibita, Mirari Echepare, Beñat Picabea, Daniel Orive, Ane Álava, Joaquín Fernández-Irigoyen, Enrique Santamaría, Allan Argueta, Eva Molina, Antonio Pineda-Lucena und 5 weitere

Cell Reports · 2026

DOI: 10.1016/j.celrep.2026.117087 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cell Reports, 2026. Verfasst von Andrea Pasquier und 16 weiteren Autor:innen. Beteiligte Einrichtung: Program in Solid Tumors, Cancer Division, CIMA-University of Navarra, Cancer Center Clínica Universidad de Navarra (CCUN), 31008 Pamplona, Spain. Hauptthemen laut MEDLINE: Receptors, Tumor Necrosis Factor, Type I, Lung Neoplasms, Signal Transduction, Autophagy-Related Protein-1 Homolog. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: European Regional Development Fund, Gobierno de Espana Ministerio de Ciencia e Innovacion, Centro de Investigación Biomédica en Red de Cáncer.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Immunotherapy has transformed the treatment of non-small cell lung cancer (NSCLC). Yet, acquired resistance remains a major clinical challenge. Defining molecular determinants of tumor sensitivity to T cell-mediated killing is therefore critical. Tumor necrosis factor α (TNF-α) released by cytotoxic T cells promotes tumor cell death, whereas NF-κB signaling supports survival. Autophagy counteracts TNFα-induced apoptosis, and its inhibition enhances responses to immune checkpoint inhibitors (ICIs). Genomic alterations further contribute to immune evasion and reduced immunotherapy efficacy. We previously identified DSTYK, a dual serine/threonine and tyrosine kinase amplified in NSCLC, as a suppressor of TNF-α-mediated CD8+ T cell killing and a driver of ICI resistance through autophagy. Here, we show that DSTYK modulates TNFR1 signaling by phosphorylating the autophagy initiator ULK1, which enables ULK1-dependent phosphorylation of RIPK1. Loss of DSTYK disrupts ULK1 activation, promotes RIPK1 autophosphorylation, proapoptotic signaling, and impaired NF-κB-dependent survival. These findings define a DSTYK-ULK1-RIPK1 axis controlling TNF-α-induced apoptosis and support targeting ULK1 to sensitize DSTYK-amplified NSCLC to T cell-mediated killing.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, Tumor Necrosis Factor, Type ILung NeoplasmsSignal TransductionAutophagy-Related Protein-1 HomologIntracellular Signaling Peptides and ProteinsDrug Resistance, NeoplasmCarcinoma, Non-Small-Cell LungHumansAnimalsCell Line, TumorReceptor-Interacting Protein Serine-Threonine KinasesPhosphorylationTumor Necrosis Factor-alphaApoptosisNF-kappa BAutophagyMice

Stichwörter der Autor:innen

CP: cancerCP: immunologyDSTYKRIPK1TNFR1 pathwayULK1apoptosisautophagylung cancer

Substanzen

Receptors, Tumor Necrosis Factor, Type IAutophagy-Related Protein-1 HomologIntracellular Signaling Peptides and ProteinsRIPK1 protein, humanULK1 protein, humanReceptor-Interacting Protein Serine-Threonine KinasesTumor Necrosis Factor-alphaNF-kappa B

Autor:innen und Institutionen

  • Program in Solid Tumors, Cancer Division, CIMA-University of Navarra, Cancer Center Clínica Universidad de Navarra (CCUN), 31008 Pamplona, Spain.
  • Program in Solid Tumors, Cancer Division, CIMA-University of Navarra, Cancer Center Clínica Universidad de Navarra (CCUN), 31008 Pamplona, Spain; Department of Biochemistry and Genetics, School of Sciences, University o…
  • Program in Solid Tumors, Cancer Division, CIMA-University of Navarra, Cancer Center Clínica Universidad de Navarra (CCUN), 31008 Pamplona, Spain; Consorcio de Investigación Biomédica en Red de Cáncer (CIBERONC), 28040 M…
  • Navarra Health Research Institute (IDISNA), 31008 Pamplona, Spain; Clinical Neuroproteomics Unit, Proteomics Platform, Navarrabiomed, Hospital Universitario de Navarra (HUN), Public University of Navarra (UPNA), 31008 P…
  • Department of Pathology, Clínica Universidad de Navarra, 31008 Pamplona, Spain.
  • Therapeutic Innovation Program, Enabling Technologies Division, CIMA-University of Navarra, Cancer Center Clínica Universidad de Navarra (CCUN), 31008 Pamplona, Spain.

Förderung

  • European Regional Development Fund
  • Gobierno de Espana Ministerio de Ciencia e Innovacion
  • Centro de Investigación Biomédica en Red de Cáncer
  • Universidad de Navarra
  • Spanish Association Against Cancer Scientific Foundation
  • Carlos III Health Institute
  • Micropalaeontological Society
  • Ministerio de Sanidad, Consumo y Bienestar Social

Zitieren

APA

Pasquier, A., Viu-Idocin, C., Arricibita, A., Echepare, M., Picabea, B., Orive, D., Álava, A., Fernández-Irigoyen, J., Santamaría, E., Argueta, A., Molina, E., Pineda-Lucena, A., Gentili, M., Facchinetti, F., Roz, L., Montuenga, L. M., & Valencia, K. (2026). Targeting the DSTYK-ULK1 axis rewires TNFR1 signaling to overcome treatment resistance in lung cancer. Cell Reports. https://doi.org/10.1016/j.celrep.2026.117087

Vancouver

Pasquier A, Viu-Idocin C, Arricibita A, Echepare M, Picabea B, Orive D, et al. Targeting the DSTYK-ULK1 axis rewires TNFR1 signaling to overcome treatment resistance in lung cancer. Cell Reports. 2026. doi:10.1016/j.celrep.2026.117087

BibTeX
@article{Pasquier2026,
  author = {Pasquier, Andrea and Viu-Idocin, Cristina and Arricibita, Andrea and Echepare, Mirari and Picabea, Beñat and Orive, Daniel and Álava, Ane and Fernández-Irigoyen, Joaquín and Santamaría, Enrique and Argueta, Allan and Molina, Eva and Pineda-Lucena, Antonio and Gentili, Marco and Facchinetti, Federica and Roz, Luca and Montuenga, Luis M and Valencia, Karmele},
  title = {Targeting the DSTYK-ULK1 axis rewires TNFR1 signaling to overcome treatment resistance in lung cancer},
  journal = {Cell Reports},
  year = {2026},
  doi = {10.1016/j.celrep.2026.117087}
}
Kostenlos starten →